Last reviewed · How we verify
Iodopovidone
Iodopovidone is a Small molecule drug developed by Universidad Tecnológica de Pereira. It is currently in Phase 3 development. Also known as: povidone-iodine solution.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Iodopovidone |
|---|---|
| Also known as | povidone-iodine solution |
| Sponsor | Universidad Tecnológica de Pereira |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 3 |
Approved indications
Common side effects
Key clinical trials
- Durability of Three Monthly Loading Doses With Faricimab in Treatment-naïve Neovascular Age-related Macular Degeneration
- Comparison of Pain Reduction in Painful Chronic Wounds With and Without Fat Grafting (NA)
- Surgical Site Preparation in Subjects Undergoing Medical Thoracoscopy (NA)
- Efficacy of Autologous Conditioned Serum in Temporomandibular Joint Disorder (NA)
- Preoperative Clindamycin Vaginal Cream Versus Vaginal Cleansing With Povidone-iodine on Postoperative Infections After Cesarean Section (PHASE4)
- CLinical Evaluation of ANtiseptic Skin Preparation in Revision Total Joint Arthroplasty of the Hip and Knee (NA)
- Povidone-Iodine Nasal Irrigation After Surgery for Chronic Rhinosinusitis (NA)
- Anterior Iliopsoas Space Block Versus PENG Block on Ease of Positioning for Spinal Anathesia in Patients Undergoing Hip Surgeries (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iodopovidone CI brief — competitive landscape report
- Iodopovidone updates RSS · CI watch RSS
- Universidad Tecnológica de Pereira portfolio CI
Frequently asked questions about Iodopovidone
What is Iodopovidone?
Who makes Iodopovidone?
Is Iodopovidone also known as anything else?
What development phase is Iodopovidone in?
Related
- Manufacturer: Universidad Tecnológica de Pereira — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: povidone-iodine solution
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing